Paola A Gehrig1, Victoria L Bae-Jump. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7572, USA. Paola_Gehrig@med.unc.edu
Abstract
OBJECTIVES: To discuss the novel agents which are being developed for the treatment of advanced and recurrent endometrial carcinoma and to review other molecular targets that may be interesting in the treatment of this disease. While the majority of women with endometrial cancer enjoy a relatively good prognosis, the options for those women who suffer from a disease recurrence are limited and there is a need to identify novel agents. METHODS: A review of clinical trials of novel therapeutic agents and their molecular targets is provided. In addition, a review of the current literature on other potential molecular targets for endometrial cancer was performed. RESULTS: Several phase II trials of novel agents, both alone and in combination with traditional cytotoxic chemotherapy, have been completed or are nearing completion. It appears that the targeted agents may have the most efficacy in combination with cytotoxic chemotherapy or in a multi-targeted agent approach. CONCLUSIONS: Chemotherapy offers the opportunity for a meaningful response rate in women with endometrial cancer, but the responses are often short lived and cure is uncommon in the setting of recurrent disease. The recent increase in molecular targets has led to the availability of many novel therapies. Determining how these agents are to be used, alone or in combination with "standard" therapies, needs to be defined and translational studies are needed to develop rational combinations of these novel agents before we can move into clinical trials. Copyright 2009 Elsevier Inc. All rights reserved.
OBJECTIVES: To discuss the novel agents which are being developed for the treatment of advanced and recurrent endometrial carcinoma and to review other molecular targets that may be interesting in the treatment of this disease. While the majority of women with endometrial cancer enjoy a relatively good prognosis, the options for those women who suffer from a disease recurrence are limited and there is a need to identify novel agents. METHODS: A review of clinical trials of novel therapeutic agents and their molecular targets is provided. In addition, a review of the current literature on other potential molecular targets for endometrial cancer was performed. RESULTS: Several phase II trials of novel agents, both alone and in combination with traditional cytotoxic chemotherapy, have been completed or are nearing completion. It appears that the targeted agents may have the most efficacy in combination with cytotoxic chemotherapy or in a multi-targeted agent approach. CONCLUSIONS: Chemotherapy offers the opportunity for a meaningful response rate in women with endometrial cancer, but the responses are often short lived and cure is uncommon in the setting of recurrent disease. The recent increase in molecular targets has led to the availability of many novel therapies. Determining how these agents are to be used, alone or in combination with "standard" therapies, needs to be defined and translational studies are needed to develop rational combinations of these novel agents before we can move into clinical trials. Copyright 2009 Elsevier Inc. All rights reserved.
Authors: Don S Dizon; John A Blessing; D Scott McMeekin; Sudarshan K Sharma; Paul Disilvestro; Ronald D Alvarez Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Howard D Homesley; Virginia Filiaci; Susan K Gibbons; Harry J Long; David Cella; Nick M Spirtos; Robert T Morris; Koen DeGeest; Roger Lee; Anthony Montag Journal: Gynecol Oncol Date: 2008-12-23 Impact factor: 5.482
Authors: Stephen Leong; Roger B Cohen; Daniel L Gustafson; Corey J Langer; D Ross Camidge; Kristin Padavic; Lia Gore; Margaret Smith; Laura Q Chow; Margaret von Mehren; Cindy O'Bryant; Sujatha Hariharan; Sami Diab; Norma Lynn Fox; Renée Miceli; S Gail Eckhardt Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: Leigh A Cantrell; Chunxiao Zhou; Alberto Mendivil; Kimberly M Malloy; Paola A Gehrig; Victoria L Bae-Jump Journal: Gynecol Oncol Date: 2009-10-12 Impact factor: 5.482
Authors: David Scott Miller; John A Blessing; Richard D Drake; Robert Higgins; D Scott McMeekin; Louis V Puneky; Carolyn N Krasner Journal: Gynecol Oncol Date: 2009-10-04 Impact factor: 5.482
Authors: Victoria L Bae-Jump; Chunxiao Zhou; John F Boggess; Young E Whang; Lisa Barroilhet; Paola A Gehrig Journal: Gynecol Oncol Date: 2010-09-21 Impact factor: 5.482
Authors: Hui Guo; Weimin Kong; Lu Zhang; Jianjun Han; Leslie H Clark; Yajie Yin; Ziwei Fang; Wenchuan Sun; Jiandong Wang; Timothy P Gilliam; Douglas Lee; Liza Makowski; Chunxiao Zhou; Victoria L Bae-Jump Journal: Am J Cancer Res Date: 2019-10-01 Impact factor: 6.166
Authors: Ji-Yeon Yang; Henrica M J Werner; Jie Li; Shannon N Westin; Yiling Lu; Mari K Halle; Jone Trovik; Helga B Salvesen; Gordon B Mills; Han Liang Journal: Clin Cancer Res Date: 2015-07-29 Impact factor: 12.531
Authors: Yang Liu; Rebecca J Whelan; Bikash R Pattnaik; Kai Ludwig; Enkateswar Subudhi; Helen Rowland; Nick Claussen; Noah Zucker; Shitanshu Uppal; David M Kushner; Mildred Felder; Manish S Patankar; Arvinder Kapur Journal: PLoS One Date: 2012-12-31 Impact factor: 3.240